Uterine myoma

Rein MS, Barbieri RL, Friedman AJ (1995) Progesterone a critical role in pathogenesis of uterine myomas. Am J Obstet Gynecol 172 14-18... 

The second data set investigated in this work consisted of 28 samples. Among them, 10 were from healthy women, eight samples were collected from uterine myoma patients, and the remaining from uterine cervical cancer patients. Five randomly selected samples in the data set were applied as the verification set. In this section, -1 represented the cancer samples, 0 represented uterine... 

Case III. The data set including the samples from the healthy women and the uterine myoma patients was also studied. The healthy samples were represented by 1, and the uterine myoma samples were denoted by 0. Of all the 18 samples, three of them selected randomly were used as verification set, and the others were training samples. When the 13 original input variables (the concentrations of the 14 kinds of nucleosides in each sample) were adopted to design the corresponding MLP ANN in 1000 iteration times with unit penalty 0.01, all the samples can be classified correctly in the model-... 

The PA mifepristone also delays or inhibits ovulation, which may produce amenorrhea [48, 49]. Amenorrhea may be a consequence of an effect at the level of the ovary, pituitary or hypothalamus. The SPRM asoprisnil, in contrast, is not so effective in inhibiting ovulation [50]. The amenorrhea consequent to PAs and SPRMs occurs with levels of estradiol in the range of the early follicular phase of the menstrual cycle [48-50]. As a result ofthe antiproliferative effect and the amenorrhea, PAs and SPRMs have been advocated in the treatment of uterine myoma, endometriosis and dysfunctional uterine bleeding. 

Eisinger, S.H., Bonfiglio, T., Fiscella, K., Meldrum, S. and Guzick, D.S. (2005) Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. Journal of Minimally Invasive Gynecology, 12, 227-233. 

Progesterone receptor antagonists and their potential clinical applications (e.g. in uterine myoma, endometriosis, breast, ovarian or uterine cancer, or as potential contraceptives) are discussed by Irving M. Spitz. 

Ravina JH, Ciraru-Vigneron, Aymard A, Le Dreff 0, Mer-land JJ (2000) Pregnancy after embolization of uterine myoma report of 12 cases. Ferti Steril 73 1241-1243... 

Pourrat XJ, Fourquet F, Guerif F, Viratelle N, Herbreteau D, Marret H. Medico-economic approach to the management of uterine myomas a 6- month cost-effectiveness study of pelvic embolization versus vaginal hysterectomy (2003) Fur J Obstet Gynecol Reprod Biol 111 59-64... 

Tanaka H, Umekawa T, Kikukawa T, Nakamura M, Toyoda N (2002) Venous thromboembolic diseases associated with uterine myomas diagnosed before hysterectomy a report of two cases. J Obstet Gynaecol Res 28 300-303... 

Hurst BS, Matthews ML, Marshburn PB (2005) Laparoscopic myomectomy for symptomatic uterine myomas. Fertil Steril 83 1-23... 

Malzoni M, Rotond M, Perone C, Labriola D, Ammaturo F, Izzo A, Panariello S, Reich H (2003) Fertility after laparoscopic myomectomy of large uterine myomas operative technique and preliminary results. Eur J Gynaecol Oncol 24 79-82... 

The levels of 8-hydroxy-2 -deoxyguanosine in DNA from uterine myoma tissues were sigifificantly (P < 0.01) elevated compared with those of tumour-free uterine tissue samples (Foksinski et al. 2000). In tumour-free uterine tissues, the levels of this modified base were higher in the group of premenopausal women when compared with postmenopausal ones (P <0.05). 

Esteve JL, Acosta R, Perez Y, Rodriguez B, Seigler 1, Sanchez C, et al. Mifepristone versus placebo to treat uterine myoma a double-blind, randomized clinical trial. Int J Womens Health 2013 5 361-9. 

Carbonell JL, Acosta R, Perez Y, Garces R, Sanchez C, Tomasi G. Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup randomized clinical trial. ISRN Obstet Gynecol 2013 2013. 649030. 

Used in modem Europe in the treatment of premenstrual and menopausal disorders including premenstmal mastodynia (mastalgia) and other symptoms of PMS also in treatments of premenstmal tension syndrome, Parkinson s disease, acne, uterine myomas, as a galactogogue, as an adjunctive therapy in endometriosis (mckenna), and upon termination of use of birth control pills also used to help re-establish normal menstmation and ovulation, to increase or stimulate milk flow reduce water retention during menstmation allay effusions in the knee joints associated with premenstmal syndrome. 

The remarkable antitumor proper gs of medrogestone (9) on uterine myomas have been announ d, and additional pharmacological evaluation was published... 

---